Early outcomes of online adaptive MR-guided SBRT for localized prostate cancer: a prospective study
Abrahams Ocanto, María González, Macarena Teja, Gloria Guardia, Gloria Sánchez, Daniela Gonsalves, Castalia Fernández, Lisselott Torres, Luis Glaría, Israel Thuissard, Miren Gaztañaga, José García, Sigfredo Elías Romero Zhogbi, Jon Andreescu, Álvaro Flores, Maia Dzhugashvili, David Esteban, Evita Krumina, Loubna Aaki, Jaume Fernández, José González, Antonio Ristori, José Begara, Daniel Rivas, Jasuani Bravo, Ana Vílchez, Luis Clemente, Juan Martínez-Salamanca, Luca Nicosia, Filippo Alongi, Andrew Loblaw, Fernando López-Campos, Felipe Couñago · 2026
Read Early outcomes of online adaptive MR-guided SBRT for localized prostate cancer: a prospective study by Abrahams Ocanto, María González, Macarena Teja, Gloria Guardia, Gloria Sánchez, Daniela Gonsalves, Castalia Fernández, Lisselott Torres, Luis Glaría, Israel Thuissard, Miren Gaztañaga, José García, Sigfredo Elías Romero Zhogbi, Jon Andreescu, Álvaro Flores, Maia Dzhugashvili, David Esteban, Evita Krumina, Loubna Aaki, Jaume Fernández, José González, Antonio Ristori, José Begara, Daniel Rivas, Jasuani Bravo, Ana Vílchez, Luis Clemente, Juan Martínez-Salamanca, Luca Nicosia, Filippo Alongi, Andrew Loblaw, Fernando López-Campos, Felipe Couñago (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13450012.txt.
Description
Abrahams Ocanto and a very large team report in 2026 early results from a prospective study of online adaptive, MR-guided stereotactic radiation for localized prostate cancer. The prostate shifts daily and sits against rectum and bladder, so the team replanned each session on fresh magnetic resonance images, allowing margins as tight as two millimeters without gel spacers. This first report concentrates on early side effects and patient-reported quality of life through one year.
Acute toxicity stayed low: side effects of grade two or worse touched three percent of patients for urinary symptoms and none for bowel symptoms. Patients themselves reported minimal impact on urinary, bowel, and overall quality of life. No biochemical failures, the blood-marker signal of returning cancer, appeared during the first year. The authors suggest the adaptive workflow itself, not margin shrinkage alone, deserves credit for the gentle safety profile, while longer follow-up tests durability.
Catalog record
| CREATOR | Abrahams Ocanto, María González, Macarena Teja, Gloria Guardia, Gloria Sánchez, Daniela Gonsalves, Castalia Fernández, Lisselott Torres, Luis Glaría, Israel Thuissard, Miren Gaztañaga, José García, Sigfredo Elías Romero Zhogbi, Jon Andreescu, Álvaro Flores, Maia Dzhugashvili, David Esteban, Evita Krumina, Loubna Aaki, Jaume Fernández, José González, Antonio Ristori, José Begara, Daniel Rivas, Jasuani Bravo, Ana Vílchez, Luis Clemente, Juan Martínez-Salamanca, Luca Nicosia, Filippo Alongi, Andrew Loblaw, Fernando López-Campos, Felipe Couñago |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |